Results 81 to 90 of about 400,933 (233)
Comparison Study of Computational Prediction Tools for Drug-Target Binding Affinities
Frontiers in Chemistry, 2019 The drug development is generally arduous, costly, and success rates are low. Thus, the identification of drug-target interactions (DTIs) has become a crucial step in early stages of drug discovery.
Maha Thafar +6 more
doaj +1 more source
, 2021 The identification of drug-target interaction (DTI) is a crucial part of the drug discovery and development process. In vitro and in vivo experiments for drug target validation and screening are, however, very expensive and take a lot of time to ...
Li, Albina
core
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Cognitive decline is a disabling and variable feature of Parkinson disease (PD). While cholinergic system degeneration is linked to cognitive impairments in PD, most prior research reported cross‐sectional associations. We aimed to fill this gap by investigating whether baseline regional cerebral vesicular acetylcholine transporter ...
Taylor Brown +6 more
wiley +1 more source
Fluorous Drug-Affinity Proteomics for Cancer Drug Discovery [PDF]
, 2015 Identifying the intracellular targets of small molecules – target ID – is a major problem in chemical biology with broad application to the discovery and development of novel therapies.
Herzberg, Benjamin
core
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan +5 more
wiley +1 more source
Efficacy of Inebilizumab in N‐MOmentum Trial Participants With or Without Prior Immunosuppressants
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT This post hoc analysis examined the impact of prior immunosuppressants on the long‐term efficacy and safety of inebilizumab, a cluster of differentiation 19+ B‐cell–depleting monoclonal antibody, in participants with aquaporin‐4–seropositive neuromyelitis optica spectrum disorder from the N‐MOmentum trial (NTC02200770).
Bruce A. C. Cree +9 more
wiley +1 more source
, 2023 Drug-target binding affinity prediction plays an important role in the early stages of drug discovery, which can infer the strength of interactions between new drugs and new targets. However, the performance of previous computational models is limited by
Chu, Jian, Yang, Genke, Yang, Xinxing
core
White Matter Microstructural Abnormalities in Neonatal Onset Genetic Epilepsy
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Recent evidence indicates that epilepsy is associated with abnormal white matter. If seizures alter white matter, then the impact upon network function, epileptogenesis, and cognition could be pronounced in neonates undergoing rapid developmental myelination. Neonates with epilepsy due to nonstructural genetic causes provide a unique
Amanda G. Sandoval Karamian +8 more
wiley +1 more source
DynHeter-DTA: Dynamic Heterogeneous Graph Representation for Drug-Target Binding Affinity Prediction
In drug development, drug-target affinity (DTA) prediction is a key indicator for assessing the drug’s efficacy and safety. Despite significant progress in deep learning-based affinity prediction approaches in recent years, there are still ...
Changli Li, Guangyue Li
core +1 more source
Halogen Bond: Its Role beyond Drug–Target Binding Affinity for Drug Discovery and Development
, 2015 Halogen bond has attracted a great deal of attention in the past years for hit-to-lead-to-candidate optimization aiming at improving drug-target binding affinity. In general, heavy organohalogens (i.e., organochlorines, organobromines, and organoiodines)
Yunxiang Lu (1305909) +5 more
core +1 more source